ClinicalTrials.gg
RecruitingNCT07111494Updated Nov 5, 2026

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

A Phase 4 interventional study of GLP-1 agonists and Nutrition Counseling in Psoriatic Arthritis (PsA), sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Medical College of Wisconsin · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
139th of 159
22 · median 228
Started
2026
with 8 others
Phase 4
18 of 194
5 open now
Primary completion
2027-10
later than 36 of 59 live
Registered
180th of 194
by date

Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 139th largest by planned enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2026, is one of 18 in phase 4, reaches primary completion later than 36 of the 59 other live ones, and was the 180th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.

The main objectives it aims to answer are:

To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling.

To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling.

Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.

03

Conditions studied

  • Psoriatic Arthritis (PsA)

Browse trials for

Keywords

  • Psoriatic Arthritis
  • GLP-1
  • Minimal Disease Activity
  • Nutrition Counseling
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age 18 and older) who present to rheumatology clinic
  • Participants must be able to read, understand, and provide documented as approved by the Institutional Review Board (IRB).
  • Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA
  • Participants must have a (BMI) of 30kg/m\^2
  • Participants must be treated for PsA in accordance with guidelines
  • Have not achieved MDA in PsA patients
  • Have a minimum TJC > 1 and SJC > at baseline
  • Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Any prior use of GLP-1 agonists
  • Inability to provide
  • Current participation in another PsA study
  • Treatment initiation by GLP-1 agonists by FDA
  • Patients with (HbA1c) > 10 at baseline
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Active comparator
    GLP-1

    Drug: GLP-1 agonists

  • Active comparator
    Nutrition Counseling

    Other: Nutrition Counseling

Interventions

06

What researchers measure

Primary outcomes

  1. Change from the baseline Minimal Disease Activity (MDA) Scores at Week 12 and 24 with GLP-1 Agonists vs Nutrition Counseling

    In order to meet Minimal Disease Activity (MDA) participants need to meet 5 of the 7 criteria: tender joint count less than or equal to 68 and greater than or equal to 1 (TJC68), swollen joint count less than or equal to 66 and greater than or equal to 1 (SJC66), psoriasis body surface area is less than or equal to 3%, patient pain Visual Analogue Scale (VAS) is less than or equal to 15mm, patient global disease activity VAS is less than or equal to 20mm, Health Assessment Questionnaire (HAQ) is less than or equal to 0.5 and tender entheseal points is less than or equal to 1. One of the outcomes of this study is to see how these scores change with the participants receiving a GLP-1 or nutrition counseling.

    Time frame: Week 12 and 24

  2. Proportion of Patients who Achieve Disease Activity in Psoriatic Arthritis (DAPSA) Remission with GLP-1 Agonists Vs. Nutrition Counseling at Week 12 and 24

    DASPA is a composite measure based on the summation of four variables: tender and swollen joints (TJC68, SJC66), C-reactive protein (CRP), Patient Global Assessment (PtGA) and Patient Pain both reported on a 0-100 mm VAS. DASPA classifications validated for PsA include Less than or equal to 4 (remission), greater than 4 but less than or equal to 14 is low disease activity. Greater than 14 but less than or equal to 28 is moderate disease activity and greater than 28 is high disease activity.

    Time frame: Week 12 and 24

07

Study locations

1 of 1 sites recruiting
  • Medical College of Wisconsin/Froedtert Hosptial
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Shikha Singla, MD · Contactssingla@mcw.edu · 414-955-7040
    • Kiley Timler · Contactktimler@mcw.edu
    • Shikha Singla, MD · Principal investigator
    • David Gazeley, MD · Sub investigator
    • Michael Putman, MD · Sub investigator
    • Lisa Morseli, MD · Sub investigator
    • Ann Rosenthal, MD · Sub investigator
    • Anam Qureshi, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data sharing at National/international conferences

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2027, 17 months after the start.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's planned 17 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
May 1, 2026
Primary completionEst.
Oct 15, 2027was Oct 2026
CompletionEst.
Oct 15, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 15, 2026→Oct 15, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Oct 15, 2026→Oct 15, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07111494
Responsible party
David Gazeley (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Aug 8, 2025
Start date
May 1, 2026
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLP-1 receptor agonists

Start the discussion